Delcath Systems (NASDAQ:DCTH) Raised to Strong-Buy at Wall Street Zen

Delcath Systems (NASDAQ:DCTH – Get Free Report) was upgraded by equities researchers at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Saturday, Wall Street Zen reports.

DCTH has been the subject of several other research reports. Zacks Research upgraded shares of Delcath Systems from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 11th. Weiss Ratings upgraded shares of Delcath Systems from a “hold (c-)” rating to a “hold (c+)” rating in a research report on Thursday. BTIG Research raised their price target on shares of Delcath Systems from $21.00 to $25.00 and gave the stock a “buy” rating in a research report on Monday, November 9th. Finally, HC Wainwright lifted their price target on shares of Delcath Systems from $32.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, November 10th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $29.33.

Check Out Our Latest Stock Report on DCTH

Delcath Systems Stock Performance

Shares of NASDAQ DCTH opened at $20.55 on Friday. Delcath Systems has a twelve month low of $8.12 and a twelve month high of $22.51. The company has a market capitalization of $714.89 million, a price-to-earnings ratio of 128.44 and a beta of 0.62. The business has a 50 day simple moving average of $15.88 and a 200-day simple moving average of $12.70.

Delcath Systems (NASDAQ:DCTH – Get Free Report) last posted its quarterly earnings results on Monday, November 9th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.26. Delcath Systems had a return on equity of 5.56% and a net margin of 6.05%. The business had revenue of $35.10 million for the quarter, compared to analyst estimates of $25.99 million. As a group, equities analysts predict that Delcath Systems will post 0.13 earnings per share for the current year.

Insider Buying and Selling at Delcath Systems

In other news, Director Bridget A. Martell sold 22,500 shares of the stock in a transaction that occurred on Thursday, November 12th. The stock was sold at an average price of $21.71, for a total transaction of $488,475.00. Following the sale, the director directly owned 22,500 shares in the company, valued at approximately $488,475. This represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 19.36% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Integrated Wealth Concepts LLC acquired a new stake in Delcath Systems in the second quarter worth $48,000. IFP Advisors Inc bought a new stake in Delcath Systems in the second quarter valued at $52,000. Royal Bank of Canada lifted its stake in Delcath Systems by 14.8% in the first quarter. Royal Bank of Canada now owns 18,383 shares of the company’s stock valued at $170,000 after buying an additional 2,364 shares during the last quarter. Entropy Technologies LP bought a new stake in Delcath Systems in the third quarter valued at $328,000. Finally, Kopp Family Office LLC bought a new stake in Delcath Systems in the third quarter valued at $450,000. Institutional investors and hedge funds own 61.12% of the company’s stock.

Delcath Systems News Roundup

These are some of the DCTH news items that stood out recently:

  • Positive Sentiment: HC Wainwright reiterated its “Buy” rating and $36 price target, raising its FY2026 EPS forecast from a loss of $0.17 to earnings of $0.13 and its FY2027 estimate from $0.12 to $0.33. It also expects a narrower Q4 2026 loss. MarketBeat analyst estimates
  • Neutral Sentiment: Delcath will be featured on “Health Uncensored with Dr. Drew” in a segment about liver-directed cancer treatment. The coverage may raise awareness, but no direct commercial or financial impact was disclosed. BioSpace announcement
  • Negative Sentiment: Director Bridget A. Martell sold 22,500 shares for about $488,475, cutting her stake by 50%. Insider sales can raise concern, though the filing does not state the reason for the transaction. SEC Form 4

About Delcath Systems

(Get Free Report)

Delcath Systems, Inc. is an oncology company focused on liver-directed treatments for cancers that have spread to the liver. Its technology uses percutaneous hepatic perfusion, a procedure that temporarily isolates the liver’s blood supply and circulates chemotherapy through the organ before filtering the blood and returning it to the patient. The company’s HEPZATO KIT combines melphalan with a specialized delivery system. The U.S. Food and Drug Administration approved it for certain adults with unresectable metastatic uveal melanoma involving the liver.

Further Reading

Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.